Evidence map›Paper›PMID 35129804›Full record

ArticleApplied biochemistry and biotechnology2022

Protective Effects of Ginkgolide on a Cellular Model of Alzheimer's Disease via Suppression of the NF-κB Signaling Pathway.

Tian-Tong Niu, He Yin, Bao-Lei Xu, Ting-Ting Yang, Hui-Qin Li, Yi Sun, Guang-Zhi Liu

Open access · hybridAbstract read
In one paragraph

Article in Applied biochemistry and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
4.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Tian-Tong Niu *Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
He Yin *Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
Bao-Lei Xu *Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
Ting-Ting YangDepartment of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
Hui-Qin LiResearch & Development Centre of Chengdu Baiyu Pharmaceutical Co., Ltd, Chengdu, 610041, China.
Yi SunResearch & Development Centre of Chengdu Baiyu Pharmaceutical Co., Ltd, Chengdu, 610041, China.
Guang-Zhi LiuDepartment of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China. guangzhi2002@hotmail.com.
Beijing Anzhen Hospital · CNCapital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

synopsisNF-κB signaling has been reported to play a key regulatory role in the pathogenesis of Alzheimer's disease (AD). The purpose of this study is to investigate the effects of ginkgolide on cell viability in an AD cellular model involving an APP/PS1 double gene-transfected HEK293 cell line (APP/PS1-HEK293) and further explore the mechanisms of action related to NF-κB signaling. The optimal time point and concentration of ginkgolide for cell proliferation were screened using a cell counting kit-8 assay. Based on the results, an in vitro study was performed by co-culture of APP/PS1-HEK293 with different dosages of ginkgolide, followed by an enzyme-linked immunosorbent assay to measure the levels of supernatant tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6, as well as western blotting and real-time polymerase chain reaction to detect intracellular protein and mRNA expression of NF-κB p65, IκBa, Bcl-2, and Bax. APP/PS1-HEK293 cells exhibited the highest cell viability at a concentration of 100 µg/ml after 48 h of treatment with ginkgolide. The supernatant levels of TNF-α, IL-1β, and IL-6 in the high-dosage ginkgolide-treated groups were lower than those in the control group. Compared with the control group, there were decreased intracellular protein and mRNA expression of NF-κB p65 and Bax, but increased protein and mRNA expression of IκBa in both high-dosage and low-dosage groups. Ginkgolide may enhance cell viability, indicative of its neuroprotective effects on AD, at least partially via suppression of the NF-κB signaling pathway involving anti-apoptosis and anti-inflammation mechanisms. Therefore, ginkgolide might be a promising therapeutic agent against AD.

Indexed as

Alzheimer DiseaseNF-kappa Bbcl-2-Associated X ProteinGinkgolidesHEK293 CellsHumansInterleukin-6RNA, MessengerSignal TransductionTumor Necrosis Factor-alphabcl-2-Associated X ProteinGinkgolidesInterleukin-6NF-kappa BRNA, MessengerTumor Necrosis Factor-alphaAlzheimer’s diseaseBilobalideGinkgolideGinkgolide BNeuroinflammationNF-κB signaling pathway

Identifiers

PMID35129804
PMCPMC9117391
OpenAlexW4210883692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.